JP2010235524A - Antihistamine agent containing pollen dumpling - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To provide an antihistamine agent containing pollen dumplings as an active constituent which can be used for various applications such as pharmaceuticals and cosmetics. <P>SOLUTION: The antihistamine agent containing pollen dumplings or a solvent extract thereof as an active constituent is used for a therapeutic or prophylactic agent for I type allergic diseases for example. <P>COPYRIGHT: (C)2011,JPO&INPIT

Description

  The present invention relates to an antihistamine that contains pollen cargo or a solvent extract of pollen cargo as an active ingredient.

  In general, pollen load is a bee that is pollen from plant stamens, rolled with honey or saliva and hardened into dumplings, and contains a variety of nutrients such as high-quality proteins, vitamins and minerals. It is also called “Perfect Food”. Pollen cargo is easily recovered from bees by a collector or the like, and is mainly consumed as a dietary supplement.

  Conventionally, pollen load is known to have several pharmacological effects. As an invention using the pharmacological effect of pollen cargo, for example, compositions disclosed in Patent Documents 1 and 2 are known. Patent Document 1 discloses a bone mass enhancing composition containing pollen cargo as an active ingredient. Patent Document 2 discloses a composition for preventing / treating diabetic disease containing pollen cargo as an active ingredient.

JP 2007-016014 A JP 2008-105982 A

  By the way, allergic diseases are known as diseases in which an immune reaction occurs excessively with respect to a specific antigen. Among these, type I allergy is known as an allergic disease mediated by histamine as a physiologically active substance. Type I allergy is also called immediate hypersensitivity. As typical diseases, for example, bronchial asthma, urticaria, atopic dermatitis, and anaphylactic shock caused by bee venom, food, drugs and the like are known. . Type I allergy is caused by the fact that IgE, an immunoglobulin, binds to mast cells (mast cells) and basophils, and when antigen is bound there, histamine that is stored as granules inside the cells is released outside the cells. Arise. Conventionally, various first generation and second generation antihistamines are known as therapeutic agents for type I allergy. However, all of them have a problem of side effects and may require careful administration.

As a result of searching for a new physiological action of the above-mentioned pollen load, the present inventors have found that the pollen load has an action of suppressing the release of histamine from mast cells and basophils.
An object of the present invention is to provide an antihistamine containing, as an active ingredient, a pollen load that can be used for various uses such as pharmaceuticals and cosmetics.

In order to achieve the above object, the antihistamine according to claim 1 is characterized by containing pollen cargo or a solvent extract of pollen cargo as an active ingredient.
The invention according to claim 2 is characterized in that the antihistamine according to claim 1 is used as a therapeutic or prophylactic agent for type I allergic diseases.

  Invention of Claim 3 is an antihistamine of Claim 1 or Claim 2, WHEREIN: The said solvent is at least 1 type chosen from the mixed liquid of water, a hydrophilic organic solvent, and a water / hydrophilic organic solvent. It is characterized by that.

  ADVANTAGE OF THE INVENTION According to this invention, the antihistamine which contains the pollen load which can be utilized for various uses, such as a pharmaceutical and cosmetics, as an active ingredient can be provided.

The figure which shows the histamine release inhibitory effect from a rat peritoneal mast cell. (A) The figure which shows the amount of histamine release | extrication at the time of adding each amount (The solid content concentration% is shown in the figure. The following is the same) of pollen cargo ethanol extract (pollen cargo ethanol extract). (B) The figure which shows the histamine release inhibitory rate at the time of adding each amount of pollen cargo ethanol extract. (C) The figure which shows the amount of histamine release at the time of adding each amount of pollen water extract (pollen water extract). (D) The figure which shows the histamine release inhibitory rate at the time of adding each amount of pollen water extract. (E) The figure which shows the amount of histamine release at the time of adding each quantity of strawberry tea water extract. (F) The figure which shows the histamine release inhibitory rate at the time of adding each quantity of strawberry tea water extract. The figure which shows the inhibitory effect of histamine release by the calcium ionophore from a rat basophilic leukemia cell. (A) The figure which shows the amount of histamine release at the time of adding each amount of pollen-loaded ethanol extract. (B) The figure which shows the amount of histamine release at the time of adding each amount of pollen water extract. (C) The figure which shows the histamine release inhibitory rate at the time of adding each amount of pollen water extract. (D) The figure which shows the amount of histamine release at the time of adding each quantity of strawberry tea water extract. (E) The figure which shows the histamine release inhibitory rate at the time of adding each quantity of strawberry tea water extract. The figure which shows the inhibitory effect of histamine release by the concanavalin A (ConA) and phosphatidylserine (PS) from a rat basophilic leukemia cell. (A) The figure which shows the amount of histamine release at the time of adding each amount of pollen-loaded ethanol extract. (B) The figure which shows the histamine release inhibitory rate at the time of adding each amount of pollen cargo ethanol extract. (C) The figure which shows the amount of histamine release at the time of adding each amount of pollen water extract. (D) The figure which shows the histamine release inhibitory rate at the time of adding each amount of pollen water extract. (E) The figure which shows the amount of histamine release at the time of adding each quantity of strawberry tea water extract. (F) The figure which shows the histamine release inhibitory rate at the time of adding each quantity of strawberry tea water extract.

Hereinafter, an embodiment embodying the antihistamine of the present invention will be described.
The antihistamine of this embodiment contains a solvent extract obtained by extracting a pollen load or a pollen load with a solvent as an active ingredient. As described above, the pollen load is obtained by bees obtained from stamens of plants, rolled up with honey or saliva, and hardened in a dumpling form, and contains various nutrients such as vitamins and minerals. The place of origin of the pollen load is not particularly limited, and may be any of, for example, Japan, China, Brazil, European countries, Oceania countries, and the United States. Moreover, the origin plant of the pollen used as the raw material of the pollen load is not particularly limited, and any plant collected by bees can be used. Examples of the plant from which pollen originates include, for example, Hannibalidae, Azalea, Perilla, Muraceae, Beech, Asteraceae, Spiraceae, Brassicaceae, Legume, Rose, and Willow. Of these, the genus Hannibalae and the Brassicaceae are preferable from the viewpoint of availability. Examples of the genus Hannibalidae include the genus Cystas. Examples of the Brassicaceae include Brassica rape and Japanese radish radish. The method for collecting pollen cargo is not particularly limited, and a known method can be appropriately employed. For example, a method using a pollen collector attached to the entrance / exit of a nest box and provided with a lattice-like stripped perforated plate, a method of directly collecting a pollen load attached to a nest plate or a bee, and the like can be mentioned.

  In this embodiment, a solvent extract obtained by subjecting the pollen cargo to extraction with a solvent other than the pollen cargo itself may be used as the active ingredient as the active ingredient. Examples of the solvent used for the extraction treatment include water, a hydrophilic organic solvent, and a water / hydrophilic organic solvent mixture. As the hydrophilic organic solvent, in addition to lower alcohols such as ethanol, methanol and isopropanol having the property of dissolving in water, ketones such as acetone and methyl ethyl ketone can be appropriately selected and used. These hydrophilic organic solvents may be used alone or in combination of two or more. Among these solvents, water or ethanol, which is more excellent in the antihistamine releasing action of the extract, can be preferably applied.

  For example, when water is used as the extraction solvent, the amount added to the pollen cargo of the solvent is preferably 1 to 10 parts by mass and more preferably 4 to 8 parts by mass with respect to 1 part by mass of the pollen cargo from the viewpoint of extraction efficiency. 5 to 6 parts by mass is most preferable. These extraction solvents are mixed and stirred with the pollen load. Although extraction temperature is suitably set according to the kind of solvent etc., it is preferable that it is 30-60 degreeC from a viewpoint of the extraction efficiency of an active ingredient. When the extraction temperature is less than 30 ° C., the separation efficiency of the dissolved component and the insoluble component is lowered, which is not preferable. On the other hand, when the extraction temperature exceeds 60 ° C., the extraction components may be denatured. The extraction time is appropriately set depending on the extraction temperature and the like, but is preferably about 4 to 48 hours, and more preferably about 5 to 20 hours. The obtained extract is composed of a water-soluble fraction and an insoluble fraction consisting of a precipitate. These soluble and insoluble fractions can be easily separated by using known methods such as filtration and centrifugation. Of these, the soluble fraction can be used as a solvent extract.

  For example, when ethanol is used as the extraction solvent, the amount added to the pollen cargo of the solvent is preferably 1 to 10 parts by mass, more preferably 4 to 8 parts by mass with respect to 1 part by mass of the pollen cargo from the viewpoint of extraction efficiency. 5 to 6 parts by mass is most preferable. These extraction solvents are mixed and stirred with the pollen load. Although extraction temperature is suitably set with the kind etc. of solvent, it is preferable that it is 10-40 degreeC from a viewpoint of the extraction efficiency of an active ingredient. When the extraction temperature is less than 10 ° C., the separation efficiency of the dissolved component and the insoluble component is lowered, which is not preferable. Conversely, when the extraction temperature exceeds 40 ° C., the extraction solvent evaporates, which may lead to a decrease in extraction efficiency. The extraction time is appropriately set depending on the extraction temperature and the like, but is preferably about 4 to 48 hours, and more preferably about 5 to 20 hours. The obtained extract is composed of a fraction soluble in ethanol solvent and an insoluble fraction consisting of a precipitate. These soluble and insoluble fractions can be easily separated by using known methods such as filtration and centrifugation. Of these, the soluble fraction can be used as a solvent extract.

  The antihistamine of this embodiment has an action of inhibiting the release of histamine from mast cells (mast cells) and basophils. Therefore, it can be applied as a therapeutic or prophylactic agent for various diseases caused by the release of histamine from mast cells and basophils. Histamine has a pharmacological action on a living body, such as blood pressure lowering, increased vascular permeability, smooth muscle contraction, vasodilation, and promotion of gland secretion. Histamine is usually stored as granules in cells such as mast cells and basophils, but IgE, an immunoglobulin, binds to mast cells and basophils, and when antigen binds to it, it is stored as granules in the cells. Histamine is released extracellularly. Examples of diseases associated with (mediated) release of histamine from mast cells and basophils include type I allergy and inflammatory reaction. Type I allergy, also called immediate hypersensitivity, binds to histamine type 1 receptors that are expressed in tissues such as smooth muscle, vascular endothelial cells, and central nerves when histamine is secreted excessively, and then decreases blood pressure and Symptoms such as asthma attacks and redness of edema are caused through physiological actions such as smooth muscle contraction. Representative diseases of type I allergy include bronchial asthma, urticaria, PIE syndrome, atopic dermatitis, allergic rhinitis, hay fever, and anaphylactic shock caused by bee venom, food and drugs (drug hypersensitivity) It has been known. Alleviation of these symptoms is expected by the antihistamine of this embodiment. Therefore, the antihistamine of this embodiment can be preferably applied as a therapeutic or prophylactic agent aimed at obtaining treatment for type I allergy, reduction of symptoms, or suppression of onset.

As a specific blending form of the antihistamine of this embodiment, it can be applied as pharmaceuticals, research reagents, cosmetics and foods and drinks for the purpose of obtaining the above-mentioned effects.
When using the antihistamine of this embodiment as a pharmaceutical, a well-known administration method can be suitably employ | adopted according to the objective etc. For example, it is possible to adopt any administration method such as intravascular administration or transdermal administration, in addition to administration by application to the affected area, administration (oral intake). As the dosage form, a known dosage form can be appropriately employed depending on the purpose of the antihistamine. For example, ointments, solutions, sprays, sheets, powders, powders, granules, tablets, capsules, pills, suppositories, injections and the like can be mentioned. Moreover, you may mix | blend an excipient | filler, a base, an emulsifier, a solvent, a stabilizer etc. as an additive.

  The antihistamine of this embodiment may be applied as a reagent for experiment and research in the form of a reagent for inhibiting histamine release from mast cells or basophils. It is suitably used in fields such as elucidation of the mechanism of physiological action related to the release of histamine and research / development of treatment methods for various symptoms.

  When applying the antihistamine of this embodiment to cosmetics, it can manufacture by mix | blending with a cosmetic base material. The form of the cosmetic may be any of emulsion, cream, powder and the like. By applying such cosmetics to the skin, it is possible to obtain effects such as an action of suppressing inflammation via histamine. Cosmetic bases are generally blended in common with cosmetics. For example, oil, purified water, and alcohol as main components, surfactants, moisturizers, antioxidants, thickeners, anti-seborrheic agents. At least one selected from an agent, a blood circulation promoter, a whitening agent, a pH adjuster, a pigment, a preservative, and a fragrance is appropriately blended.

  When applying the antihistamine of this embodiment to food-drinks, it can be used by adding to various food materials or beverage materials. The form of the food or drink is not particularly limited, and may be any of liquid, powder, gel, solid, etc. The dosage form is any of tablets, capsules, granules, drinks, etc. It may be. Among these, a capsule is preferable because hygroscopicity is suppressed. As said food-drinks, you may mix | blend gelatinizer containing foodstuffs, saccharides, a fragrance | flavor, a sweetener, fats and oils, a base material, an excipient | filler, a food additive, a subsidiary material, a bulking agent etc. suitably as another component.

The effects exhibited by this embodiment will be described below.
(1) In this embodiment, the pollen load or the solvent extract of the pollen load has a high antihistamine action. Therefore, it can be preferably applied to pharmaceuticals, research reagents, cosmetics, and foods and drinks intended for antihistaminic activity as antihistamines.

  (2) The antihistamine of this embodiment is preferably used as a therapeutic or prophylactic agent for type I allergic diseases. Type I allergies are allergies through the release of histamine from mast cells and antibasophils. Therefore, the antihistamine of this embodiment is a therapeutic agent for bronchial asthma, urticaria, atopic dermatitis, and anaphylactic shock caused by bee venom, food and drugs, which are typical symptoms of type I allergy. Or it can apply preferably as a preventive agent.

  (3) In the antihistamine of this embodiment, the solvent used for obtaining the pollen cargo solvent extract is preferably water, a hydrophilic organic solvent, or a water / hydrophilic organic solvent mixture. Therefore, since the content of impurities is less than that of using pollen cargo itself as an active ingredient, a more effective antihistamine action can be exhibited.

  (4) In this embodiment, a pollen load which is a natural material or a solvent extract thereof is used as an active ingredient of an antihistamine. Therefore, there is no possibility of causing side effects, and it can be safely applied to various uses.

  (5) When the antihistamine of this embodiment contains pollen cargo as an active ingredient, the pollen cargo contains various nutrients such as vitamins and minerals. It can be carried out.

In addition, you may change the said embodiment as follows.
-The antihistamine of the above embodiment may be applied not only to pharmaceuticals, cosmetics and foods and drinks applied to humans, but also to pharmaceuticals for domestic animals such as livestock.

  -The antihistamine of the above embodiment is applied not only for the treatment of symptoms of diseases associated with the release of histamine from mast cells and anti-basophils but also for the prevention of the onset of symptoms of the diseases. May be.

Although the test example is given below and the embodiment is described more specifically, the present invention is not limited to these.
(Production Example 1)
A pollen load was obtained from a honeybee's nest box in which cistus genus Jara etc. exist as surrounding plants within a radius of several kilometers. To 100 g of the pollen load, 600 g of ethanol as an extraction solvent was added and extracted by stirring at room temperature for 4 hours. Then, the agitation extract of the pollen load is filtered with a filter paper (No. 2 manufactured by Advantech Toyo Co., Ltd.) to separate the residue insoluble in ethanol and the supernatant (extract), thereby obtaining 30 g of extract (solid content) 4% by mass) was obtained. This was designated as pollen loaded ethanol extract (Pollen loaded ethanol extract) in Production Example 1.

(Production Example 2)
A pollen load was obtained from a honeybee's nest box in which cistus genus Jara etc. exist as surrounding plants within a radius of several kilometers. To 100 g of the pollen load, 600 g of water as an extraction solvent was added and extracted by stirring at 60 ° C. for 6 hours. And the filtered extract (No. 2 made by Advantech Toyo Co., Ltd.) is filtered through the agitation extract of the above-mentioned pollen load, and the residue insoluble in water and the supernatant (extract) are separated to obtain 50 g of extract (solid content 7.5% by mass). This was designated as Pollen Water Extract (Pollen Water Extract) in Production Example 2.

(Test Example 1: Histamine release inhibition test from mast cells)
With regard to the antihistamine action, which is one of the physiologically active actions of pollen cargo, the histamine release inhibitory action was measured using rat intraperitoneal mast cells. The pollen cargo solvent extract of the said manufacture examples 1 and 2 was used as a sample. As a positive target, a strawberry tea water extract (manufactured by Matsuura Pharmaceutical Co., Ltd., solid content 100%) was used. Each sample was diluted with a phosphate buffered physiological saline so that the solid content would be the respective amounts shown in FIG.

Wistar male rats were used as test animals. After the rats were lethal by ether anesthesia, 20 mL of phosphate buffered saline (Dulbecco's Phosphate Buffered Saline: D-PBS (+), manufactured by Nacalai Tesque) was injected into the peritoneal cavity, and the intraperitoneal fluid was collected. The collected liquid was centrifuged at 1200 rpm, 4 ° C. for 5 minutes, and the supernatant was removed. Further, the cell suspension obtained by adding 5 mL of phosphate buffered saline (D-PBS (−), calcium and magnesium free, manufactured by Nacalai Tesque) was centrifuged at 1200 rpm, 4 ° C. for 5 minutes to obtain the supernatant. The removal was repeated twice to create a uniform cell suspension. The number of cells was measured with a hemocytometer, and adjusted to 4 × 10 ⁵ cells / mL to obtain a mast cell suspension.

  First, 2.5 mL of mast cell suspension was dispensed into a 15 mL plastic tube, 0.5 mL of each sample prepared so that the solid content concentration was the above predetermined amount was added, and then a 37 ° C. water bath was added. For 5 minutes. As a degranulation inducer, Compound 48/80 (manufactured by Sigma-Aldrich Japan) 0.5 mL (10 μg / mL) was added, followed by culturing in a water bath at 37 ° C. for 10 minutes. The reaction was stopped in ice water for 5 minutes. The mast cells were removed by centrifugation at 1200 rpm and 4 ° C. for 5 minutes, the supernatant was collected, and the amount of free histamine was measured. The analysis of histamine was performed using a commercially available histamine measurement kit (Check Color Histamine, manufactured by Kikkoman Corporation). The inhibition rate of histamine release was calculated from the following formula.

Histamine release inhibition rate (%) = [(ac)-(bc)] / (ac) × 100
a shows the amount of histamine in the supernatant of the mast cell suspension added with the degranulation inducer (extract 0%). b shows the amount of histamine in the supernatant of the mast cell suspension to which the degranulation inducer and the pollen-loaded solvent extract or strawberry tea water extract were added. c indicates the amount of histamine in the supernatant of the mast cell suspension (baseline). The results of the amount of histamine released and the histamine release inhibition rate are shown in FIG. Further, a calibration curve was prepared, and an 80% inhibitory concentration of histamine release (solid extract concentration) was calculated. The results are shown in Table 1.

図１に示されるように、花粉荷のエタノール抽出エキス及び水抽出エキス共に、ラット腹腔内マスト細胞からのヒスタミン遊離を濃度依存的に抑制することが確認された。表１に示されるように、マスト細胞からのヒスタミン遊離を抑制する作用は、花粉荷の水抽出エキスよりエタノール抽出エキスの方が高いことが確認される。

As shown in FIG. 1, it was confirmed that both the ethanol extract and the water extract of pollen loaded inhibit histamine release from rat peritoneal mast cells in a concentration-dependent manner. As shown in Table 1, it is confirmed that the action of suppressing the release of histamine from mast cells is higher in the ethanol extract than the water extract of pollen.

(Test Example 2: Histamine release inhibition test from rat basophilic leukemia cells)
The antihistamine action, which is one of the physiologically active actions of pollen cargo, was measured for inhibitory action on histamine release using rat basophilic leukemia cells. The pollen cargo solvent extract of the said manufacture examples 1 and 2 was used as a sample. As a positive target, a strawberry tea water extract (manufactured by Matsuura Pharmaceutical Co., Ltd., solid content 100%) was used. Each sample was diluted with a phosphate buffered physiological saline so that the solid content would be the respective amounts shown in FIG.

As rat basophilic leukemia cells, RBL-2H3 cells were treated with 10% non-immobilized fetal bovine serum (manufactured by Sigma-Aldrich Japan), penicillin (100 U / mL, manufactured by Nacalai Tesque) and streptomycin (0.1 mg / mL). And pre-cultured under conditions of 5% CO ₂ and 37 ° C. in Dulbecco's modified Eagle's medium (D-MEM, Sigma-Aldrich Japan) containing Nacalai Tesque. After completion of the preculture, the cells were detached using a 0.25% trypsin-1 mM EDTA solution (manufactured by Nacalai Tesque). Cells were collected by centrifugation at 1000 rpm, 4 ° C., 5 minutes. The number of cells was measured with a hemocytometer, and adjusted to 4 × 10 ⁵ cells / mL was used as the RBL-2H3 cell suspension.

First, 500 μL (2 × 10 ⁵ cells / well) of RBL-2H3 cell suspension was seeded in a 24-well culture plate and cultured under conditions of 5% CO ₂ and 37 ° C. for 12 hours. After completion of the culture, the medium was removed, and each well was washed with PBS (−). After adding 400 μL of L-glutamine and Phenol Red-free D-MEM medium (manufactured by Sigma Aldrich Japan) to each well, 50 μL of each sample prepared so that the solid content concentration is the above predetermined amount was added, The cells were cultured for 30 minutes under conditions of 5% CO ₂ and 37 ° C. Assuming different mechanism of action, as degranulation inducers, calcium ionophore (A23187, manufactured by Wako Pure Chemical Industries), IgE receptor agonist concanavalin A (Con A, manufactured by Wako Pure Chemical Industries) and phosphatidylserine ( Two types of combinations of PS and Funakoshi were used. In A23187, 50 μL (10 μg / mL) was added to each well, and then cultured for 30 minutes under conditions of 5% CO ₂ and 37 ° C. In ConA (2 mg / mL) and PS (0.5 mg / mL), 25 μL was added to each well, and then cultured for 60 minutes under conditions of 5% CO ₂ and 37 ° C. The culture supernatant of each well was collected, centrifuged at 1000 rpm at 4 ° C. for 5 minutes to remove RBL-2H3 cells, and then the amount of free histamine was measured.

The analysis of histamine was performed using a commercially available histamine measurement kit (Check Color Histamine, manufactured by Kikkoman Corporation). The inhibition rate of histamine release was calculated from the following formula.
Histamine release inhibition rate (%) = (ab) / a × 100
a shows the amount of histamine in the culture supernatant to which a degranulation inducer is added (extract 0%). b shows the amount of histamine in the culture supernatant to which the degranulation inducer and the pollen cargo solvent extract or persimmon tea water extract were added. The results of the amount of released histamine and the inhibition rate of histamine release are shown in FIGS. The result of the inhibitory effect of histamine release by calcium ionophore from rat basophilic leukemia cells is shown in FIG. The result of the inhibitory effect of histamine release by concanavalin A (ConA) and phosphatidylserine (PS) from rat basophilic leukemia cells is shown in FIG. Further, a calibration curve was prepared, and an 80% inhibitory concentration of histamine release (solid extract concentration) was calculated. The results are shown in Table 2.

脱顆粒誘発剤としてＡ２３１８７を用いた場合、花粉荷水抽出エキスにＲＢＬ−２Ｈ３細胞からのヒスタミン遊離を濃度依存的に抑制する効果が確認された。一方、花粉荷エタノール抽出エキスには、ヒスタミン遊離の抑制効果は確認されなかった。脱顆粒誘発剤としてＣｏｎＡ及びＰＳの組み合わせを用いた場合、花粉荷のエタノール抽出エキス及び水抽出エキス共に、ＲＢＬ−２Ｈ３細胞からのヒスタミン遊離の抑制効果が確認された。以上の結果より、花粉荷のエタノール抽出エキスは、細胞膜を安定化させることによりヒスタミン遊離を阻害している可能性が示唆される。一方、花粉荷の水抽出エキスは、カルシウム流入工程以降のシグナル伝達系を阻害している可能性が示唆される。

When A23187 was used as a degranulation inducer, the pollen water extract extract was confirmed to have an effect of inhibiting histamine release from RBL-2H3 cells in a concentration-dependent manner. On the other hand, the pollen-loaded ethanol extract did not confirm the inhibitory effect on histamine release. When the combination of ConA and PS was used as a degranulation inducer, the inhibitory effect of histamine release from RBL-2H3 cells was confirmed for both the ethanol extract and the water extract of pollen cargo. From the above results, it is suggested that the ethanol extract of pollen cargo may inhibit histamine release by stabilizing the cell membrane. On the other hand, it is suggested that the water extract of pollen cargo may inhibit the signal transduction system after the calcium inflow process.

Next, technical ideas that can be grasped from the above-described embodiment and other examples will be described below together with their effects.
(A) Pharmaceuticals, research reagents, cosmetics, and foods and drinks containing the antihistamines.

(B) The said antihistamine whose said hydrophilic organic solvent is ethanol.
(C) A degranulation inhibitor or histamine release inhibitor in mast cells or basophils, comprising pollen cargo or a solvent extract of pollen cargo as an active ingredient.

Claims (3)

  An antihistamine, comprising pollen cargo or a solvent extract of pollen cargo as an active ingredient.   The antihistamine according to claim 1, wherein the antihistamine is used as a therapeutic or prophylactic agent for type I allergic diseases.   3. The antihistamine according to claim 1, wherein the solvent is at least one selected from water, a hydrophilic organic solvent, and a mixed solution of water / hydrophilic organic solvent.

Images